nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—CYP2D6—Niacin—atherosclerosis	0.0721	0.169	CbGbCtD
Lisuride—CYP2D6—Simvastatin—atherosclerosis	0.057	0.134	CbGbCtD
Lisuride—CYP2D6—Lovastatin—atherosclerosis	0.0558	0.131	CbGbCtD
Lisuride—CYP2D6—Pravastatin—atherosclerosis	0.0558	0.131	CbGbCtD
Lisuride—CYP3A4—Ezetimibe—atherosclerosis	0.039	0.0916	CbGbCtD
Lisuride—CYP3A4—Rosuvastatin—atherosclerosis	0.039	0.0916	CbGbCtD
Lisuride—CYP3A4—Simvastatin—atherosclerosis	0.0362	0.0851	CbGbCtD
Lisuride—CYP3A4—Pravastatin—atherosclerosis	0.0355	0.0833	CbGbCtD
Lisuride—CYP3A4—Lovastatin—atherosclerosis	0.0355	0.0833	CbGbCtD
Lisuride—Regurgitation—Lovastatin—atherosclerosis	0.0177	0.0839	CcSEcCtD
Lisuride—Regurgitation—Simvastatin—atherosclerosis	0.0165	0.0785	CcSEcCtD
Lisuride—HTR2A—arteriole—atherosclerosis	0.00686	0.144	CbGeAlD
Lisuride—Libido increased—Niacin—atherosclerosis	0.00609	0.0289	CcSEcCtD
Lisuride—Nightmare—Rosuvastatin—atherosclerosis	0.00492	0.0233	CcSEcCtD
Lisuride—HTR2A—vein—atherosclerosis	0.00409	0.086	CbGeAlD
Lisuride—Nightmare—Simvastatin—atherosclerosis	0.0039	0.0185	CcSEcCtD
Lisuride—Nightmare—Pravastatin—atherosclerosis	0.00352	0.0167	CcSEcCtD
Lisuride—HTR1B—artery—atherosclerosis	0.00346	0.0728	CbGeAlD
Lisuride—HTR1D—artery—atherosclerosis	0.00335	0.0705	CbGeAlD
Lisuride—HTR2A—hindlimb—atherosclerosis	0.00272	0.0571	CbGeAlD
Lisuride—HTR1B—blood vessel—atherosclerosis	0.0027	0.0567	CbGeAlD
Lisuride—Disturbance in sexual arousal—Niacin—atherosclerosis	0.00267	0.0127	CcSEcCtD
Lisuride—HTR1D—blood vessel—atherosclerosis	0.00261	0.0549	CbGeAlD
Lisuride—Abdominal discomfort—Lovastatin—atherosclerosis	0.0026	0.0123	CcSEcCtD
Lisuride—Orthostatic hypotension—Niacin—atherosclerosis	0.00246	0.0117	CcSEcCtD
Lisuride—Abdominal discomfort—Simvastatin—atherosclerosis	0.00243	0.0115	CcSEcCtD
Lisuride—HTR2A—appendage—atherosclerosis	0.00233	0.049	CbGeAlD
Lisuride—Mental disorder—Rosuvastatin—atherosclerosis	0.00224	0.0106	CcSEcCtD
Lisuride—Oedema peripheral—Ezetimibe—atherosclerosis	0.00209	0.00994	CcSEcCtD
Lisuride—Weight increased—Pravastatin—atherosclerosis	0.00208	0.00989	CcSEcCtD
Lisuride—Weight decreased—Pravastatin—atherosclerosis	0.00207	0.00983	CcSEcCtD
Lisuride—Sweating—Niacin—atherosclerosis	0.00199	0.00944	CcSEcCtD
Lisuride—Cough—Rosuvastatin—atherosclerosis	0.00194	0.00922	CcSEcCtD
Lisuride—Angiopathy—Ezetimibe—atherosclerosis	0.00193	0.00915	CcSEcCtD
Lisuride—Immune system disorder—Ezetimibe—atherosclerosis	0.00192	0.00911	CcSEcCtD
Lisuride—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00192	0.00909	CcSEcCtD
Lisuride—Mental disorder—Ezetimibe—atherosclerosis	0.00186	0.00884	CcSEcCtD
Lisuride—Malnutrition—Ezetimibe—atherosclerosis	0.00185	0.00878	CcSEcCtD
Lisuride—Oedema peripheral—Niacin—atherosclerosis	0.00183	0.0087	CcSEcCtD
Lisuride—Confusional state—Rosuvastatin—atherosclerosis	0.00183	0.0087	CcSEcCtD
Lisuride—Infection—Rosuvastatin—atherosclerosis	0.0018	0.00857	CcSEcCtD
Lisuride—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00178	0.00846	CcSEcCtD
Lisuride—Mental disorder—Simvastatin—atherosclerosis	0.00178	0.00843	CcSEcCtD
Lisuride—Cardiac disorder—Pravastatin—atherosclerosis	0.0017	0.00807	CcSEcCtD
Lisuride—Vertigo—Lovastatin—atherosclerosis	0.00169	0.00805	CcSEcCtD
Lisuride—Angiopathy—Niacin—atherosclerosis	0.00169	0.00802	CcSEcCtD
Lisuride—HTR2A—artery—atherosclerosis	0.00167	0.035	CbGeAlD
Lisuride—Insomnia—Rosuvastatin—atherosclerosis	0.00164	0.0078	CcSEcCtD
Lisuride—Palpitations—Ezetimibe—atherosclerosis	0.00164	0.00776	CcSEcCtD
Lisuride—Malnutrition—Niacin—atherosclerosis	0.00162	0.00769	CcSEcCtD
Lisuride—Cough—Ezetimibe—atherosclerosis	0.00161	0.00766	CcSEcCtD
Lisuride—Anxiety—Lovastatin—atherosclerosis	0.0016	0.0076	CcSEcCtD
Lisuride—Vertigo—Simvastatin—atherosclerosis	0.00159	0.00753	CcSEcCtD
Lisuride—Dry mouth—Lovastatin—atherosclerosis	0.00157	0.00746	CcSEcCtD
Lisuride—Constipation—Rosuvastatin—atherosclerosis	0.00155	0.00738	CcSEcCtD
Lisuride—Confusional state—Lovastatin—atherosclerosis	0.00155	0.00737	CcSEcCtD
Lisuride—Dry mouth—Ezetimibe—atherosclerosis	0.00154	0.00731	CcSEcCtD
Lisuride—Infection—Lovastatin—atherosclerosis	0.00153	0.00726	CcSEcCtD
Lisuride—Confusional state—Ezetimibe—atherosclerosis	0.00152	0.00723	CcSEcCtD
Lisuride—Infection—Ezetimibe—atherosclerosis	0.0015	0.00712	CcSEcCtD
Lisuride—Feeling abnormal—Rosuvastatin—atherosclerosis	0.0015	0.00711	CcSEcCtD
Lisuride—Anxiety—Simvastatin—atherosclerosis	0.0015	0.00711	CcSEcCtD
Lisuride—Nervous system disorder—Ezetimibe—atherosclerosis	0.00148	0.00703	CcSEcCtD
Lisuride—Anorexia—Lovastatin—atherosclerosis	0.00147	0.00697	CcSEcCtD
Lisuride—Vertigo—Niacin—atherosclerosis	0.00146	0.00691	CcSEcCtD
Lisuride—Syncope—Niacin—atherosclerosis	0.00145	0.0069	CcSEcCtD
Lisuride—Confusional state—Simvastatin—atherosclerosis	0.00145	0.00689	CcSEcCtD
Lisuride—Vertigo—Pravastatin—atherosclerosis	0.00143	0.0068	CcSEcCtD
Lisuride—Palpitations—Niacin—atherosclerosis	0.00143	0.0068	CcSEcCtD
Lisuride—Infection—Simvastatin—atherosclerosis	0.00143	0.00679	CcSEcCtD
Lisuride—Cough—Niacin—atherosclerosis	0.00141	0.00671	CcSEcCtD
Lisuride—HTR2A—endothelium—atherosclerosis	0.00141	0.0296	CbGeAlD
Lisuride—Insomnia—Lovastatin—atherosclerosis	0.00139	0.00661	CcSEcCtD
Lisuride—Cough—Pravastatin—atherosclerosis	0.00139	0.00661	CcSEcCtD
Lisuride—Anorexia—Simvastatin—atherosclerosis	0.00137	0.00652	CcSEcCtD
Lisuride—Dyspnoea—Lovastatin—atherosclerosis	0.00137	0.00652	CcSEcCtD
Lisuride—Insomnia—Ezetimibe—atherosclerosis	0.00137	0.00648	CcSEcCtD
Lisuride—Anxiety—Pravastatin—atherosclerosis	0.00135	0.00643	CcSEcCtD
Lisuride—Dry mouth—Niacin—atherosclerosis	0.00135	0.0064	CcSEcCtD
Lisuride—Dyspnoea—Ezetimibe—atherosclerosis	0.00135	0.00639	CcSEcCtD
Lisuride—HTR1D—connective tissue—atherosclerosis	0.00134	0.0282	CbGeAlD
Lisuride—Decreased appetite—Lovastatin—atherosclerosis	0.00134	0.00635	CcSEcCtD
Lisuride—Fatigue—Lovastatin—atherosclerosis	0.00133	0.0063	CcSEcCtD
Lisuride—Constipation—Lovastatin—atherosclerosis	0.00132	0.00625	CcSEcCtD
Lisuride—Confusional state—Pravastatin—atherosclerosis	0.00131	0.00623	CcSEcCtD
Lisuride—Decreased appetite—Ezetimibe—atherosclerosis	0.00131	0.00623	CcSEcCtD
Lisuride—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.0013	0.00619	CcSEcCtD
Lisuride—Asthenia—Rosuvastatin—atherosclerosis	0.0013	0.00619	CcSEcCtD
Lisuride—Insomnia—Simvastatin—atherosclerosis	0.0013	0.00618	CcSEcCtD
Lisuride—Fatigue—Ezetimibe—atherosclerosis	0.0013	0.00618	CcSEcCtD
Lisuride—ADRB1—connective tissue—atherosclerosis	0.0013	0.0274	CbGeAlD
Lisuride—HTR2A—blood vessel—atherosclerosis	0.0013	0.0273	CbGeAlD
Lisuride—Infection—Pravastatin—atherosclerosis	0.00129	0.00614	CcSEcCtD
Lisuride—Constipation—Ezetimibe—atherosclerosis	0.00129	0.00613	CcSEcCtD
Lisuride—Tachycardia—Niacin—atherosclerosis	0.00129	0.00613	CcSEcCtD
Lisuride—Dyspnoea—Simvastatin—atherosclerosis	0.00128	0.00609	CcSEcCtD
Lisuride—Hyperhidrosis—Niacin—atherosclerosis	0.00128	0.00607	CcSEcCtD
Lisuride—Feeling abnormal—Lovastatin—atherosclerosis	0.00127	0.00602	CcSEcCtD
Lisuride—Anorexia—Niacin—atherosclerosis	0.00126	0.00598	CcSEcCtD
Lisuride—Hyperhidrosis—Pravastatin—atherosclerosis	0.00126	0.00598	CcSEcCtD
Lisuride—Decreased appetite—Simvastatin—atherosclerosis	0.00125	0.00594	CcSEcCtD
Lisuride—Feeling abnormal—Ezetimibe—atherosclerosis	0.00124	0.00591	CcSEcCtD
Lisuride—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00124	0.0059	CcSEcCtD
Lisuride—Fatigue—Simvastatin—atherosclerosis	0.00124	0.00589	CcSEcCtD
Lisuride—Anorexia—Pravastatin—atherosclerosis	0.00124	0.00589	CcSEcCtD
Lisuride—Constipation—Simvastatin—atherosclerosis	0.00123	0.00585	CcSEcCtD
Lisuride—HTR1B—cardiovascular system—atherosclerosis	0.0012	0.0253	CbGeAlD
Lisuride—Dizziness—Rosuvastatin—atherosclerosis	0.0012	0.0057	CcSEcCtD
Lisuride—Insomnia—Niacin—atherosclerosis	0.0012	0.00568	CcSEcCtD
Lisuride—Feeling abnormal—Simvastatin—atherosclerosis	0.00119	0.00563	CcSEcCtD
Lisuride—Dyspnoea—Niacin—atherosclerosis	0.00118	0.0056	CcSEcCtD
Lisuride—Insomnia—Pravastatin—atherosclerosis	0.00118	0.00559	CcSEcCtD
Lisuride—Somnolence—Niacin—atherosclerosis	0.00118	0.00558	CcSEcCtD
Lisuride—HTR1D—cardiovascular system—atherosclerosis	0.00116	0.0245	CbGeAlD
Lisuride—Dyspnoea—Pravastatin—atherosclerosis	0.00116	0.00551	CcSEcCtD
Lisuride—Decreased appetite—Niacin—atherosclerosis	0.00115	0.00546	CcSEcCtD
Lisuride—Gastrointestinal disorder—Niacin—atherosclerosis	0.00114	0.00542	CcSEcCtD
Lisuride—Headache—Rosuvastatin—atherosclerosis	0.00114	0.0054	CcSEcCtD
Lisuride—ADRB1—cardiovascular system—atherosclerosis	0.00113	0.0238	CbGeAlD
Lisuride—Decreased appetite—Pravastatin—atherosclerosis	0.00113	0.00537	CcSEcCtD
Lisuride—Fatigue—Pravastatin—atherosclerosis	0.00112	0.00533	CcSEcCtD
Lisuride—Constipation—Pravastatin—atherosclerosis	0.00111	0.00529	CcSEcCtD
Lisuride—Asthenia—Lovastatin—atherosclerosis	0.0011	0.00524	CcSEcCtD
Lisuride—HTR2B—cardiovascular system—atherosclerosis	0.00108	0.0228	CbGeAlD
Lisuride—Asthenia—Ezetimibe—atherosclerosis	0.00108	0.00514	CcSEcCtD
Lisuride—Feeling abnormal—Pravastatin—atherosclerosis	0.00107	0.00509	CcSEcCtD
Lisuride—Asthenia—Simvastatin—atherosclerosis	0.00103	0.0049	CcSEcCtD
Lisuride—Dizziness—Lovastatin—atherosclerosis	0.00102	0.00483	CcSEcCtD
Lisuride—Dizziness—Ezetimibe—atherosclerosis	0.000999	0.00474	CcSEcCtD
Lisuride—ADRB1—adipose tissue—atherosclerosis	0.000998	0.021	CbGeAlD
Lisuride—Vomiting—Lovastatin—atherosclerosis	0.000979	0.00465	CcSEcCtD
Lisuride—HTR1A—cardiovascular system—atherosclerosis	0.000971	0.0204	CbGeAlD
Lisuride—Headache—Lovastatin—atherosclerosis	0.000965	0.00458	CcSEcCtD
Lisuride—Vomiting—Ezetimibe—atherosclerosis	0.00096	0.00456	CcSEcCtD
Lisuride—HTR2B—adipose tissue—atherosclerosis	0.000956	0.0201	CbGeAlD
Lisuride—Dizziness—Simvastatin—atherosclerosis	0.000952	0.00452	CcSEcCtD
Lisuride—Asthenia—Niacin—atherosclerosis	0.000949	0.0045	CcSEcCtD
Lisuride—Headache—Ezetimibe—atherosclerosis	0.000946	0.00449	CcSEcCtD
Lisuride—Asthenia—Pravastatin—atherosclerosis	0.000934	0.00443	CcSEcCtD
Lisuride—Vomiting—Simvastatin—atherosclerosis	0.000916	0.00435	CcSEcCtD
Lisuride—Headache—Simvastatin—atherosclerosis	0.000902	0.00428	CcSEcCtD
Lisuride—Dizziness—Niacin—atherosclerosis	0.000874	0.00415	CcSEcCtD
Lisuride—Dizziness—Pravastatin—atherosclerosis	0.000861	0.00409	CcSEcCtD
Lisuride—Vomiting—Niacin—atherosclerosis	0.000841	0.00399	CcSEcCtD
Lisuride—Headache—Niacin—atherosclerosis	0.000828	0.00393	CcSEcCtD
Lisuride—Vomiting—Pravastatin—atherosclerosis	0.000828	0.00393	CcSEcCtD
Lisuride—Headache—Pravastatin—atherosclerosis	0.000816	0.00387	CcSEcCtD
Lisuride—ADRA2A—connective tissue—atherosclerosis	0.000782	0.0165	CbGeAlD
Lisuride—ADRA2C—adipose tissue—atherosclerosis	0.000752	0.0158	CbGeAlD
Lisuride—HTR2A—connective tissue—atherosclerosis	0.000665	0.014	CbGeAlD
Lisuride—ADRA2A—adipose tissue—atherosclerosis	0.0006	0.0126	CbGeAlD
Lisuride—HTR2A—cardiovascular system—atherosclerosis	0.000579	0.0122	CbGeAlD
Lisuride—ADRA2C—liver—atherosclerosis	0.000527	0.0111	CbGeAlD
Lisuride—HTR2A—liver—atherosclerosis	0.000358	0.00753	CbGeAlD
Lisuride—CYP3A4—liver—atherosclerosis	0.000331	0.00697	CbGeAlD
Lisuride—CYP2D6—liver—atherosclerosis	0.000326	0.00686	CbGeAlD
Lisuride—HTR1A—Signaling Pathways—NOS3—atherosclerosis	1.21e-05	3.81e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—SERPINE1—atherosclerosis	1.2e-05	3.8e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	1.2e-05	3.8e-05	CbGpPWpGaD
Lisuride—DRD1—GPCR downstream signaling—AKT1—atherosclerosis	1.2e-05	3.8e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—NOS3—atherosclerosis	1.2e-05	3.79e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.2e-05	3.79e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MMP9—atherosclerosis	1.19e-05	3.77e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—F2—atherosclerosis	1.19e-05	3.77e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—INS—atherosclerosis	1.19e-05	3.76e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCL2—atherosclerosis	1.19e-05	3.76e-05	CbGpPWpGaD
Lisuride—ADRA1D—GPCR downstream signaling—AKT1—atherosclerosis	1.19e-05	3.75e-05	CbGpPWpGaD
Lisuride—DRD3—GPCR downstream signaling—AKT1—atherosclerosis	1.19e-05	3.75e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—ALB—atherosclerosis	1.19e-05	3.75e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—IL6—atherosclerosis	1.18e-05	3.74e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	1.18e-05	3.73e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—LPL—atherosclerosis	1.18e-05	3.72e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCL2—atherosclerosis	1.17e-05	3.7e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IGF1—atherosclerosis	1.17e-05	3.69e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—IL6—atherosclerosis	1.17e-05	3.69e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—IL6—atherosclerosis	1.17e-05	3.69e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—NOS3—atherosclerosis	1.17e-05	3.69e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	1.16e-05	3.68e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.16e-05	3.68e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	1.16e-05	3.67e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	1.16e-05	3.66e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—STAT3—atherosclerosis	1.15e-05	3.65e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IGF1—atherosclerosis	1.15e-05	3.63e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	1.15e-05	3.63e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—GPX1—atherosclerosis	1.15e-05	3.63e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	1.14e-05	3.61e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	1.14e-05	3.61e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—NOS3—atherosclerosis	1.13e-05	3.58e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—STAT3—atherosclerosis	1.13e-05	3.57e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MMP9—atherosclerosis	1.13e-05	3.56e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—VEGFA—atherosclerosis	1.12e-05	3.55e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—CXCL8—atherosclerosis	1.12e-05	3.54e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—CD36—atherosclerosis	1.12e-05	3.53e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—NFKB1—atherosclerosis	1.11e-05	3.52e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—STAT3—atherosclerosis	1.11e-05	3.51e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MMP9—atherosclerosis	1.11e-05	3.51e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MMP9—atherosclerosis	1.11e-05	3.51e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	1.11e-05	3.51e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	1.11e-05	3.5e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	1.1e-05	3.48e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.1e-05	3.48e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—NFKB1—atherosclerosis	1.1e-05	3.47e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—NFKB1—atherosclerosis	1.1e-05	3.47e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MAPK8—atherosclerosis	1.09e-05	3.46e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	1.09e-05	3.46e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—AKT1—atherosclerosis	1.09e-05	3.45e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	1.09e-05	3.45e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—INS—atherosclerosis	1.08e-05	3.42e-05	CbGpPWpGaD
Lisuride—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	1.08e-05	3.42e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MAPK8—atherosclerosis	1.08e-05	3.41e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MAPK8—atherosclerosis	1.08e-05	3.41e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	1.08e-05	3.41e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—AKT1—atherosclerosis	1.08e-05	3.41e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—AKT1—atherosclerosis	1.08e-05	3.41e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	1.07e-05	3.39e-05	CbGpPWpGaD
Lisuride—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	1.07e-05	3.39e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	1.07e-05	3.38e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	1.07e-05	3.38e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	1.06e-05	3.37e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—IL6—atherosclerosis	1.06e-05	3.36e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	1.06e-05	3.36e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MAPK3—atherosclerosis	1.06e-05	3.36e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—STAT3—atherosclerosis	1.06e-05	3.35e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.06e-05	3.35e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NOS3—atherosclerosis	1.06e-05	3.35e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	1.05e-05	3.33e-05	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—IL6—atherosclerosis	1.05e-05	3.33e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	1.05e-05	3.31e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	1.05e-05	3.31e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NOS3—atherosclerosis	1.04e-05	3.29e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PPARA—atherosclerosis	1.04e-05	3.29e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTGS2—atherosclerosis	1.04e-05	3.28e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	1.04e-05	3.27e-05	CbGpPWpGaD
Lisuride—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	1.03e-05	3.27e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TGFB1—atherosclerosis	1.03e-05	3.26e-05	CbGpPWpGaD
Lisuride—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	1.03e-05	3.25e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	1.02e-05	3.22e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—IL6—atherosclerosis	1.02e-05	3.22e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	1.01e-05	3.21e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—IL6—atherosclerosis	1.01e-05	3.2e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MMP9—atherosclerosis	1.01e-05	3.2e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—VEGFA—atherosclerosis	1.01e-05	3.2e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AGT—atherosclerosis	1.01e-05	3.18e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	1e-05	3.17e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	1e-05	3.17e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—STAT3—atherosclerosis	1e-05	3.16e-05	CbGpPWpGaD
Lisuride—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	1e-05	3.16e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—VEGFA—atherosclerosis	9.97e-06	3.15e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—VEGFA—atherosclerosis	9.97e-06	3.15e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	9.93e-06	3.14e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	9.92e-06	3.14e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—STAT3—atherosclerosis	9.87e-06	3.12e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—STAT3—atherosclerosis	9.87e-06	3.12e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—APOE—atherosclerosis	9.86e-06	3.12e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	9.84e-06	3.11e-05	CbGpPWpGaD
Lisuride—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	9.84e-06	3.11e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	9.84e-06	3.11e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	9.83e-06	3.11e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	9.81e-06	3.1e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ABCA1—atherosclerosis	9.8e-06	3.1e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—CAV1—atherosclerosis	9.77e-06	3.09e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	9.75e-06	3.08e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—APOA1—atherosclerosis	9.75e-06	3.08e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	9.72e-06	3.07e-05	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—AKT1—atherosclerosis	9.7e-06	3.07e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	9.69e-06	3.06e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MMP9—atherosclerosis	9.68e-06	3.06e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MMP9—atherosclerosis	9.63e-06	3.04e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	9.57e-06	3.03e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MAPK3—atherosclerosis	9.56e-06	3.02e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	9.52e-06	3.01e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	9.48e-06	3e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MAPK3—atherosclerosis	9.43e-06	2.98e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MAPK3—atherosclerosis	9.43e-06	2.98e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	9.41e-06	2.98e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CXCL8—atherosclerosis	9.39e-06	2.97e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	9.38e-06	2.97e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	9.36e-06	2.96e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	9.36e-06	2.96e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	9.34e-06	2.95e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TGFB1—atherosclerosis	9.27e-06	2.93e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	9.26e-06	2.93e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	9.24e-06	2.92e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	9.21e-06	2.91e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TGFB1—atherosclerosis	9.15e-06	2.89e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TGFB1—atherosclerosis	9.15e-06	2.89e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	9.12e-06	2.88e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	9.11e-06	2.88e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	9.08e-06	2.87e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	9.08e-06	2.87e-05	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	9.07e-06	2.87e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	9e-06	2.85e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—atherosclerosis	8.99e-06	2.84e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	8.96e-06	2.83e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	8.94e-06	2.83e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—IL6—atherosclerosis	8.93e-06	2.82e-05	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	8.93e-06	2.82e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	8.91e-06	2.82e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CG—atherosclerosis	8.9e-06	2.81e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—IL6—atherosclerosis	8.79e-06	2.78e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	8.69e-06	2.75e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	8.64e-06	2.73e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—atherosclerosis	8.6e-06	2.72e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	8.59e-06	2.72e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PPARG—atherosclerosis	8.59e-06	2.72e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—atherosclerosis	8.56e-06	2.71e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	8.51e-06	2.69e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MMP9—atherosclerosis	8.5e-06	2.69e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—INS—atherosclerosis	8.42e-06	2.66e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—HMOX1—atherosclerosis	8.41e-06	2.66e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	8.41e-06	2.66e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	8.41e-06	2.66e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NFKB1—atherosclerosis	8.41e-06	2.66e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MMP9—atherosclerosis	8.36e-06	2.64e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	8.34e-06	2.64e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	8.32e-06	2.63e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	8.27e-06	2.62e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	8.27e-06	2.62e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK8—atherosclerosis	8.26e-06	2.61e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	8.26e-06	2.61e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—atherosclerosis	8.24e-06	2.61e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	8.22e-06	2.6e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	8.19e-06	2.59e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	8.18e-06	2.59e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	8.13e-06	2.57e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	8.12e-06	2.57e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	8.11e-06	2.56e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—IL6—atherosclerosis	8.06e-06	2.55e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—APOB—atherosclerosis	8.05e-06	2.55e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	7.99e-06	2.53e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	7.97e-06	2.52e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	7.95e-06	2.52e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	7.93e-06	2.51e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—IL6—atherosclerosis	7.89e-06	2.49e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTM1—atherosclerosis	7.83e-06	2.48e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	7.83e-06	2.48e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—IL6—atherosclerosis	7.76e-06	2.45e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—ALB—atherosclerosis	7.72e-06	2.44e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	7.72e-06	2.44e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—LPL—atherosclerosis	7.69e-06	2.43e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—VEGFA—atherosclerosis	7.63e-06	2.41e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	7.6e-06	2.4e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	7.59e-06	2.4e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—atherosclerosis	7.55e-06	2.39e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	7.52e-06	2.38e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	7.51e-06	2.37e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GPX1—atherosclerosis	7.5e-06	2.37e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—atherosclerosis	7.43e-06	2.35e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—atherosclerosis	7.43e-06	2.35e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—IL6—atherosclerosis	7.41e-06	2.34e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	7.4e-06	2.34e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—NOS3—atherosclerosis	7.39e-06	2.34e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	7.38e-06	2.33e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CD36—atherosclerosis	7.31e-06	2.31e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—atherosclerosis	7.28e-06	2.3e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK3—atherosclerosis	7.22e-06	2.28e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—atherosclerosis	7.16e-06	2.26e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	7.1e-06	2.25e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TGFB1—atherosclerosis	7e-06	2.21e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—IL6—atherosclerosis	6.99e-06	2.21e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—MTHFR—atherosclerosis	6.92e-06	2.19e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—IL6—atherosclerosis	6.89e-06	2.18e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—IL6—atherosclerosis	6.89e-06	2.18e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	6.89e-06	2.18e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—atherosclerosis	6.84e-06	2.16e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	6.83e-06	2.16e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PPARA—atherosclerosis	6.79e-06	2.15e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	6.76e-06	2.14e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTGS2—atherosclerosis	6.76e-06	2.14e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AGT—atherosclerosis	6.58e-06	2.08e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	6.46e-06	2.04e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—atherosclerosis	6.45e-06	2.04e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—APOE—atherosclerosis	6.45e-06	2.04e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—atherosclerosis	6.42e-06	2.03e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CAV1—atherosclerosis	6.39e-06	2.02e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—APOA1—atherosclerosis	6.37e-06	2.02e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—atherosclerosis	6.36e-06	2.01e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—atherosclerosis	6.36e-06	2.01e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL6—atherosclerosis	6.28e-06	1.99e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	6.27e-06	1.98e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL6—atherosclerosis	6.22e-06	1.97e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL6—atherosclerosis	6.01e-06	1.9e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL6—atherosclerosis	5.98e-06	1.89e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CG—atherosclerosis	5.82e-06	1.84e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL6—atherosclerosis	5.81e-06	1.84e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—atherosclerosis	5.8e-06	1.83e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	5.74e-06	1.82e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL6—atherosclerosis	5.72e-06	1.81e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PPARG—atherosclerosis	5.61e-06	1.78e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—atherosclerosis	5.54e-06	1.75e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—atherosclerosis	5.52e-06	1.74e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—INS—atherosclerosis	5.51e-06	1.74e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	5.36e-06	1.7e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	5.28e-06	1.67e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL6—atherosclerosis	5.28e-06	1.67e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—atherosclerosis	5.21e-06	1.65e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL6—atherosclerosis	5.19e-06	1.64e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ALB—atherosclerosis	5.05e-06	1.6e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—atherosclerosis	4.87e-06	1.54e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—NOS3—atherosclerosis	4.83e-06	1.53e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—atherosclerosis	4.79e-06	1.51e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL6—atherosclerosis	4.72e-06	1.49e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS2—atherosclerosis	4.42e-06	1.4e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	4.36e-06	1.38e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—atherosclerosis	3.4e-06	1.07e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—atherosclerosis	2.22e-06	7.02e-06	CbGpPWpGaD
